|
[1]李家斌, 姚阳, 李旭, 等.干扰素抗体产生规律性及对疗效影响初探[J].中华实验和临床病毒学杂志, 2000, 14 (2) ∶196-197.
|
|
[2]Jorns C, Holzinger D, Thimme R, et al.Rapid and simple detection of IFN-neutralizing antibodies in chronic hepatitis C non-respon-sive to IFN-alpha[J].J Med Virol, 2006, 78 (1) ∶74-82.
|
|
[3]Hou C, Chuang WL, Yu ML, et al.Incidence and associated factors of neutralizing anti-interferon antibodies among chronic hepatitis C patients treated with interferon in Taiwan[J].Scand J Gastroenterol, 2000, 35 (12) ∶1288-1293.
|
|
[4]白菡, 赵桂珍, 王贺玲, 等.干扰素治疗慢性丙型肝炎中出现反跳与干扰素抗体关系的研究[J].中国医科大学学报, 2001, 30 (4) ∶285-287.
|
|
[5]Arai K, Shindo M, Okuno T.Anti-interferon antibody in chronic hepatitis C[J].Nippon Rinsho, 1994, 52 (7) ∶1929-1934.
|
|
[6]Giannelli G, Antonelli G, Fera G, et al.Biological and clinical sig-nificance of neutralizing and binding antibodies to interferon-alpha (IFN-alpha) during therapy for chronic hepatitis C[J].Clin Exp Immunol, 1994, 97 (1) ∶4-9.
|
|
[7]Milella M, Antonelli G, Santantonio T, et al.Neutralizing antibodies to recombinant alpha-interferon and response to therapy in chronic hepatitis C virus infection[J].Liver, 1993, 13 (3) ∶146-150.
|
|
[8]李智伟, 刘沛, 白菡, 等.干扰素与病毒唑联合治疗慢性丙型肝炎疗效及与干扰素抗体关系的探讨[J].中国实用内科杂志, 2002, 22 (7) ∶399-40.
|
|
[9]Antonelli G, Giannelli G, Currenti M, et al.Antibodies to interferon (IFN) in hepatitis C patients relapsing while continuing recombinant IFN-alpha2therapy[J].Clin Exp Immunol, 1996, 104 (3) ∶384-387.
|
|
[10]Habu D, Mizuno M, Ohnishi K, et al.The influence of anti-in-terferon-alpha2a antibodies in initial daily four-week interferon-alpha2a therapy for chronic hepatitis C[J].Nippon Shokakibyo Gakkai Zasshi, 1997, 94 (5) ∶319-327.
|
|
[11]赵湘平, 邓万芳.观察丙型肝炎患者用干扰素治疗中干扰素抗体对疗效的影响[J].临床和实验医学杂志, 2006, 5 (3) ∶279.
|
|
[12]Leroy V, Baud M, de Traversay C, et al.Role of anti-interferon antibodies in breakthrough occurrence during alpha2a and2b therapy in patients with chronic hepatitis C[J].J Hepatol, 1998, 28 (3) ∶375-381.
|
|
[13]王健, 李朝品, 贾夫洋, 等.慢性丙肝患者血清干扰素抗体检测及其临床意义[J].山东医药, 2003, 43 (10) ∶1-3.
|
|
[14]Boo I, Fischer A E, Johnson D, et al.Neutralizing antibodies in pa-tients with chronic hepatitis C infection treated with (Peg) -inter-feron/ribavirin[J].J Clin Virol, 2007, 39 (4) ∶288-294.
|
|
[15]陈青锋, 郭振华, 杨彦麟, 等.慢性丙型肝炎干扰素抗体及血清分型与派罗欣疗效关系探讨[J].国际流行病学传染病学杂志, 2006, 33 (4) ∶232-234.
|
|
[16]陈青锋, 郭振华, 肖萍, 等.甘肃地区HCV血清分型与基因分型及干扰素抗体关系研究[J].国际检验医学杂志, 2006, 27 (7) ∶612-614.
|
|
[17]Ford JA, Cheong-Lee C.The role of hepatology nurse in the diffi-cult-to-treat hepatitis C population[J].Can J Gastroenterol, 2007, 21 (6) ∶353-354.
|
|
[18]Zeuzem S.Difficult-to-treat patients with chronic hepatitis C[J].Praxis, 2006, 95 (38) ∶1459-64.
|
|
[19]Bonetti P, Diodati G, Drago C, et al.Interferon antibodies in pa-tients with chronic hepatitic C virus infection treated with recombi-nant interferon alpha-2alpha[J].J Hepatol, 1994, 20 (3) ∶416-420.
|
|
[20]毛乾国, 骆抗先, 张明霞, 等.重组α-干扰素治疗慢性乙型肝炎时干扰素中和抗体的产生及影响因素[J].第一军医大学学报, 2003, 23 (12) ∶1319-1322.
|
|
[21]童福易, 唐永煌, 白敬羽, 等.病毒性肝炎患者α-干扰素中和抗体发生率及其时间规律的研究[J].临床肝胆病杂志, 1999, 15 (1) ∶38-40.
|
|
[22]陈慧.不同亚型干扰素抗体对乙型肝炎病毒疗效的影响[J].肝脏, 2003, 8 (4) ∶33.
|
|
[23]Bonino F, Baldi M, Negro F, et al.Clinical relevance of anti-in-terferon antibodies in the serum of chronic hepatitis C patients trea-ted with interferon-alpha[J].J Interferon Cytokine Res, 1997, 17 (1) ∶35-38.
|
DownLoad: